Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

2.6.1.7: kynurenine-oxoglutarate transaminase

This is an abbreviated version!
For detailed information about kynurenine-oxoglutarate transaminase, go to the full flat file.

Word Map on EC 2.6.1.7

Reaction

L-kynurenine
+
2-oxoglutarate
=
4-(2-aminophenyl)-2,4-dioxobutanoate
 +
L-glutamate

Synonyms

AadAT, aminoadipate aminotransferase, aminotransferase, kynurenine, aspartate aminotransferase, Bna3, CCBL2, cysteine conjugate beta-lyase 1, cysteine conjugate beta-lyase 2, glutamic-oxaloacetic transaminase 2, glutamine transaminase K, KAT, KAT I, KAT II, KAT III, KAT IV, KAT-1, KAT-I, KAT-II, KAT2, KAT3, KAT3/GTL/CCBL2, KYAT3, kynurenine 2-oxoglutarate transaminase, kynurenine aminotransferase, kynurenine aminotransferase 2, kynurenine aminotransferase 3, kynurenine aminotransferase I, kynurenine aminotransferase II, kynurenine aminotransferase III, kynurenine aminotransferase IV, kynurenine aminotransferase-1, kynurenine aminotransferase-I, kynurenine aminotransferase-IV, kynurenine aminotransferases I, kynurenine aminotransferases II, kynurenine pyruvate aminotransferase, kynurenine transaminase (cyclizing), kynurenine-2-oxoglutarate aminotransferase, kynurenine/alpha-aminoadipate aminotransferase, L-kynurenine aminotransferase, mitochondrial aspartate aminotransferase, More, PhKAT, phKAT-II, type II kynurenine aminotransferase

ECTree

     2 Transferases
         2.6 Transferring nitrogenous groups
             2.6.1 Transaminases
                2.6.1.7 kynurenine-oxoglutarate transaminase

Inhibitors

Inhibitors on EC 2.6.1.7 - kynurenine-oxoglutarate transaminase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(2R)-2-(5,6-dichloro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-phenylpropanoic acid
-
(2S)-2-(5,6-dichloro-1,3-dioxo-2,3-dihydro-1H-inden-2-yl)-3-phenylpropanoic acid
reversible inhibitor
(2S)-2-amino-4-[4-(ethylsulfonyl)phenyl]-4-oxobutanoic acid
reversible inhibitor
(3R)-3-amino-6-benzyl-1-hydroxy-7-methoxy-3,4-dihydroquinolin-2(1H)-one
irreversible inhibitor
(3S)-3-amino-1-hydroxy-3,4-dihydroquinolin-2(1H)-one
(3S)-3-amino-6-benzyl-1-hydroxy-7-methoxy-3,4-dihydroquinolin-2(1H)-one
-
(5S)-5-amino-7-hydroxy-2-phenyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-b]pyridin-6-one
irreversible inhibitor
(5Z)-5-[3-(4-oxo-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-7-yl)benzylidene]-1,3-thiazolidine-2,4-dione
reversible inhibitor
-
(6R)-8-cyclopropyl-N-(3,5-dimethylphenyl)-9-oxo-2,8-diazaspiro[5.5]undecane-2-carboxamide
-
(6R)-8-cyclopropyl-N-(4-methoxyphenyl)-9-oxo-2,8-diazaspiro[5.5]undecane-2-carboxamide
-
(6R)-N-(3-chloro-4-fluorophenyl)-8-(cyclopropylmethyl)-9-oxo-2,8-diazaspiro[5.5]undecane-2-carboxamide
-
(6R)-N-(3-ethylphenyl)-8-(3-methylbutyl)-9-oxo-2,8-diazaspiro[5.5]undecane-2-carboxamide
-
(6S)-8-cyclopropyl-N-(3,5-dimethylphenyl)-9-oxo-2,8-diazaspiro[5.5]undecane-2-carboxamide
-
(6S)-8-cyclopropyl-N-(4-methoxyphenyl)-9-oxo-2,8-diazaspiro[5.5]undecane-2-carboxamide
-
(6S)-N-(3-chloro-4-fluorophenyl)-8-(cyclopropylmethyl)-9-oxo-2,8-diazaspiro[5.5]undecane-2-carboxamide
-
(6S)-N-(3-ethylphenyl)-8-(3-methylbutyl)-9-oxo-2,8-diazaspiro[5.5]undecane-2-carboxamide
-
(R)-2-amino-4-(4-(ethylsulfonyl)phenyl)-4-oxobutanoic acid
-
71% inhibition at 1 mM, 63% inhibition at 0.1 mM, poor substrate that undergo slow transamination, KM-value 4.5 mM, Kcat-value 0.15 1/sec, pH 7.5, 25°C
(S)-(-)-9-(4-aminopiperazin-1-yl)-8-fluoro-3-methyl-6-oxo-2,3-dihydro-6H-1-oxa-3a-azaphenalene-5-carboxylic acid
BFF-122
(S)-(4)-(ethylsulfonyl)benzoylalanine
-
no inhibition of the human enzyme
(S)-4-ethylsulfonylbenzoylalanine
-
specific inhibitor of KAT II
(S)-9-(4-aminopiperazine-1-yl)-8-fluoro-3-methyl-6-oxo-2,3,5,6-tetrahydro-4H-1-oxa-3a-azaphenalene-5-carboxylic acid
-
BFF 122, KAT II activity is totally blocked at 0.01 mM, 43% inhibition of KAT II at 0.001 mM, 26% inhibition of KAT I at 1 mM
2-Aminoadipate
-
-
2-oxoadipate
-
-
2-oxoglutarate
3,5-difluoro-N-[5-(1-phenylcyclopropyl)-1,3,4-thiadiazol-2-yl]benzenesulfonamide
-
3,5-difluoro-N-{5-[(2R)-2-(3-fluorophenyl)-3-methylbutyl]-1,3,4-thiadiazol-2-yl}benzenesulfonamide
-
3,5-difluoro-N-{5-[(2S)-2-(3-fluorophenyl)-3-methylbutyl]-1,3,4-thiadiazol-2-yl}benzenesulfonamide
-
3,5-difluoro-N-{5-[2-(3-fluorophenyl)-3-methylbutyl]-1,3,4-thiadiazol-2-yl}benzenesulfonamide
-
3-(2-carboxyethyl)-5-chloro-1H-indole-2-carboxylic acid
-
-
3-(2-carboxyethyl)-5-nitro-1H-indole-2-carboxylic acid
-
-
3-hydroxykynurenine
3-indolepropionic acid
3-Methyl-2-benzothiazolone hydrazone hydrochloride
Hansenula schneggii
-
0.1 mM, complete inhibition, reversible by pyridoxal phosphate
4-(5,6-dichloro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)benzenesulfonamide
reversible inhibitor
4-(5,6-dichloro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethylbenzenesulfonamide
reversible inhibitor
4-carboxy-3-hydroxyphenylglycine
-
inhibition of brain KAT II
4-chloro-N-(pyrrolidin-3-yl)-2-(trifluoromethyl)benzenesulfonamide
-
4-chloromercuribenzoate
5-(2-(3-chlorophenyl)hydrazono)-6-ethoxy-6-oxohexanoic acid
-
-
5-(2-(4-bromophenyl)hydrazono)-6-ethoxy-6-oxohexanoic acid
-
-
5-(2-(4-chlorophenyl) hydrazono)-6-ethoxy-6-oxohexanoic acid
-
-
5-bromo-3-(2-carboxyethyl)-1H-indole-2-carboxylic acid
-
-
6-ethoxy-5-(2-(4-iodophenyl)hydrazono)-6-oxohexanoic acid
-
-
6-ethoxy-5-(2-(4-methoxyphenyl)hydrazono)-6-oxohexanoic acid
-
-
6-ethoxy-5-(2-(4-nitrophenyl)hydrazono)-6-oxohexanoic acid
-
-
6-ethoxy-6-oxo-5-(2-p-tolylhydrazono)hexanoic acid
-
-
adipate
alpha-aminoadipate
-
strong inhibition of KAT II
amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropionic acid
-
inhibitory in whole cells
aminoadipate
Aminooxyacetate
-
aminooxyacetic acid
-
inhibitory in whole cells
aminooxyphenylpropionic acid
-
anthranilate
-
weak inhibition
azelaic acid
-
-
BFF-122
BFF-816
carbenoxolone
highly selective and competitive inhibitor for isoform KAT2
cysteine
cysteine sulfinate
-
poor substrate that undergoes slow transamination, KM-value 12.3 mM, pH 7.5, 25°C
Decanoic acid
-
-
Dicarboxylic acids
Diethylglutaric acid
-
-
dimethylglutaric acid
-
-
DL-indole-3-lactic acid
EGTA
-
strong inhibition at pH 6.8 and Ca2+ concentrations below 0.5 mM
estradiol disulfate
Estrone sulfate
weak inhibitor
glutamate
glutamine
glycyrrhetinic acid
highly selective and competitive inhibitor for isoform KAT2
glycyrrhizic acid
highly selective and competitive inhibitor for isoform KAT2
hydroxylamine
indole-3-acetic acid
-
Indole-3-propionic acid
Indole-3-pyruvate
-
5 mM, complete inhibition
indole-3-pyruvic acid
-
iodoacetate
Isonicotinic acid hydrazide
-
anti-tuberculosis drug, enzyme is inhibited in animals fed with a diet containing isonicotinic acid hydrazide and by injection of the drug
KCN
-
complete inhibition
Kynurenate
-
weak inhibition
L- glutamate
-
5 mM decreases KAT II activity
L-2-amino-4-phosphonobutyric acid
-
inhibition of brain KAT II
L-2-aminoadipate
-
L-4-chlorokynurenine
-
-
L-5-chlorokynurenine
-
-
L-asparagine
L-aspartate
L-Cycloserine
Hansenula schneggii
-
0.1 mM, 88% inhibition, reversible by pyridoxal phosphate
L-cysteate
-
5.38 mM, 50% inhibition of brain KAT I, 1.55 mM, 50% inhibition of brain KAT II
L-cysteine
L-cysteine sulfinate
-
0.002 mM, 50% inhibition of brain KAT II
L-glutamate
L-glutamine
L-histidine
L-Homocysteate
-
5.0 mM, 50% inhibition of brain KAT I, 2.1 mM, 50% inhibition of brain KAT II
L-Homocysteine sulfinate
-
1.59 mM, 50% inhibition of brain KAT II
L-kynurenine
L-leucine
L-lysine
L-methionine
L-Penicillamine
Hansenula schneggii
-
0.1 mM, 62% inhibition, reversible by pyridoxal phosphate
L-phenylalanine
L-serine-O-phosphate
-
inhibition of brain KAT II
L-tryptophan
methionine
N-(3-chloro-4-methylphenyl)-8-(3-methylbutyl)-9-oxo-2,8-diazaspiro[5.5]undecane-2-carboxamide
-
N-(3-ethylphenyl)-8-(3-methylbutyl)-9-oxo-2,8-diazaspiro[5.5]undecane-2-carboxamide
-
N-benzyl-1-[6-methyl-5-(oxan-4-yl)-7-oxo-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]-D-prolinamide
reversible inhibitor
N-ethylmaleimide
Hansenula schneggii
-
-
N-omega-nitro-L-arginine
-
-
N-[5-(cyclopentylmethyl)-1,3,4-oxadiazol-2-yl]benzenesulfonamide
-
nicotinate
-
weak inhibition
NS-1502
reversible inhibitor; reversible inhibitor
PF-04859989
phenylhydrazine
Hansenula schneggii
-
0.1 mM, 81% inhibition, reversible by pyridoxal phosphate
phosphate
-
-
pimelate
pyridoxal 5'-phosphate
-
at high concentrations
quinolinic acid
-
strong inhibition at pH 6.8 and Ca2+ concentrations below 0.5 mM
quisqualate
Quisqualic acid
-
1 mM, isoform KAT I, 81% residual activity, isoform KAT II, 1% residual activity
S-4-(ethylsulfonyl)benzoyl-L-alanine
S-dichlorovinyl-L-cysteine
Sulfate or phosphate esters of steroids
-
-
-
trans-3-indolacrylic acid
-
trans-pyrrolidine-2,4-dicarboxylate
-
inhibition of brain KAT II
Tris amine
-
the commonly used buffer for KAT I assays greatly inhibits KAT I around neutral pH conditions, but shows no inhibition at basic pH condition
tryptophan
xanthurenate
-
weak inhibition
additional information
-